Hypothesis

Combining oral NMN with a low dose of resveratrol will increase SIRT1 enzymatic activity in human peripheral blood mononuclear cells and skeletal muscle beyond the effect of either agent alone, due to allosteric activation of SIRT1 by resveratrol that lowers its Km for NAD+.

Rationale

• NMN supplementation reliably doubles circulating NAD+ in humans (see [1][2]), yet no trial has directly measured SIRT1 activity.
• Resveratrol binds the SIRT1 regulatory site and enhances catalytic turnover in vitro [3][4].
• NAD+ concentration alone predicts only fractional SIRT1 saturation; activators can shift the enzyme's dose‑response curve, permitting significant flux at physiological NAD+ levels [5].
• Therefore, co‑administration should produce a synergistic rise in deacetylation of SIRT1 substrates that neither agent achieves singly.

Mechanistic Insight

Resveratrol stabilizes the SIRT1‑NAD+ binding pocket, decreasing the Michaelis constant (Km) for NAD+ by roughly 40% in recombinant assays. When NMN raises intracellular NAD+ to ~2‑fold basal, the lowered Km translates into a >1.5‑fold increase in Vmax‑equivalent activity. This predicts measurable deacetylation of targets such as p53 (Lys382), FOXO3a, and PGC‑1α even when NAD+ remains below the concentrations used in cell‑culture activation studies.

Proposed Protocol

• Design: randomized, double‑blind, four‑arm crossover trial (placebo, NMN 500 mg/day, resveratrol 150 mg/day, NMN + resveratrol) with 2‑week washout.
• Duration: 4 weeks per arm.
• Participants: 30 healthy adults aged 45‑65, baseline NAD+ measured in PBMCs.
• Primary outcome: SIRT1 activity in PBMCs assessed by a fluorometric deacetylation assay using a acetyl‑lysine peptide substrate.
• Secondary outcomes: Western blot quantification of acetyl‑p53 (Lys382), acetyl‑FOXO3a (Lys290), and acetyl‑PGC‑1α in PBMCs and, in a subset, vastus lateralis biopsies collected after a standardized bout of endurance exercise.
• Covariates: fasting status, physical activity, dietary niacin intake.

Expected Outcomes

1. The combination arm will show a ≥30% rise in SIRT1 activity relative to placebo (p<0.01), whereas NMN or resveratrol alone will yield ≤10% change.
2. Corresponding reductions in acetyl‑p53 and acetyl‑FOXO3a will be evident only in the combination arm.
3. Post‑exercise muscle biopsies will display greater deacetylation of PGC‑1α in the combination group, linking SIRT1 activation to mitochondrial biogenesis signaling.

Falsifiability

If the combination does not produce a statistically significant increase in SIRT1 activity or target deacetylation beyond the additive expectation of the monotherapies (i.e., the observed effect ≤ sum of individual effects), the hypothesis is falsified. Additionally, a lack of change in muscle PGC‑1α acetylation despite PBMC SIRT1 activation would challenge the assumption of tissue‑specific synergistic signaling.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC9735188/ [2] https://www.nmn.com/news/scientists-unveil-results-from-human-trial-directly-comparing-three-nad-precursors [3] https://doi.org/10.1038/nature04612 [4] https://doi.org/10.1016/j.cell.2004.12.012 [5] https://doi.org/10.1038/nrd4023